Noticias de EDIT_US

Noticias del mercado

Últimas noticias sobre EDIT_US — 51 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: EDIT_US ✕ 51 resultados
27/03/2026 EDIT_US — Stock Titan
CRISPR patent win bolsters Editas Medicine (NASDAQ: EDIT) IP estate
27/03/2026 EDIT_US — TipRanks
USPTO Ruling Impacts Editas Medicine CRISPR IP Position
27/03/2026 EDIT_US — GlobeNewswire
Editas Medicine Announces U.S. Patent and Trademark Office
27/03/2026 EDIT_US — Stock Titan
A key U.S. CRISPR patent fight swings again toward Editas partner Broad
26/03/2026 EDIT_US — Stock Titan
[SCHEDULE 13G/A] Editas Medicine, Inc. Amended Passive Investment Disclosure
25/03/2026 EDIT_US — MarketBeat ES ← EN
Estimaciones de EPS del segundo trimestre para Editas Medicine disminuidas por analista
24/03/2026 EDIT_US — MarketBeat ES ← EN
La investigación de Zacks influye en las ganancias del año fiscal 2028 de Editas Medicine
22/03/2026 EDIT_US — Stock Titan ES ← EN
Si invirtió $ 1,000 en Editas Medicine Inc (EDITAR)
16/03/2026 EDIT_US — Stock Titan
Editas Medicine (EDIT) CFO receives grant of 292,856 stock options
15/03/2026 EDIT_US — Yahoo Finance
Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401
10/03/2026 EDIT_US — TradingView ES ← EN
EDITAR Abastecerse ante una pérdida menor de lo esperado en el cuarto trimestre, los ingresos aumentan año tras año
10/03/2026 EDIT_US — GuruFocus
Editas Medicine (EDIT) Receives Upgrade to 'Buy' from Jones Trad
10/03/2026 EDIT_US — TipRanks
Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects
10/03/2026 EDIT_US — Finviz
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y
10/03/2026 EDIT_US — Yahoo Finance
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y
10/03/2026 EDIT_US — Minichart
Editas Medicine 2025 Annual Report: CRISPR Gene Editing Pipeline, EDIT-401 Program, Intellectual Property, and Industry Competition
09/03/2026 EDIT_US — Investing.com
Editas Medicine stock rises 2% after Q4 earnings and revenue beats
09/03/2026 EDIT_US — GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
09/03/2026 EDIT_US — Stock Titan
Gene edit slashes cholesterol 90% in tests; human trial next for Editas
09/03/2026 EDIT_US — Stock Titan
Editas Medicine (Nasdaq: EDIT) cuts 2025 loss and pushes EDIT-401 toward trials

Página 2 de 3

keyboard_arrow_up